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The microenvironment of solid tumours is defined by the inter-
actions between malignant tumour cells and host cells, a process in
which cytokines play an important role. We and others (Miller 
et al, 1994; McAdam et al, 1995) have utilized gene transfection
techniques to manipulate tumour cells to release a given cytokine
in an attempt to enhance the host immune response to tumours. In
preclinical models, these cytokine gene-transduced tumour cells
have been shown to generate systemic anti-tumour immunity, and
in some cases to eradicate micrometastases (Fearon et al, 1990;
Gansbacher et al, 1990; Colombo et al, 1991). Although these
results have led to the initiation of numerous clinical trials, there
are some difficulties with this approach (Jaffee and Pardoll, 1997).
One problem is that in patients with large tumour burdens, the host
immune system appears to be overwhelmed, and thus the response
is ineffective. These results suggest that it may be necessary to
employ other treatment modalities to reduce the tumour load prior
to using immunotherapy.
The combination of radiotherapy and cytokine-based
immunotherapy is appealing in that initial radiotherapy could be
used to decrease the tumour bulk, thus allowing the immune
system to be more effective. In addition, generation of anti-tumour
immunity could result in long-lived memory cells that could be
efficacious against metastases arising after eradication of the
primary tumour. Recent reports that manipulation of cytokine
expression by tumour cells can also alter their response to radia-
tion (McBride et al, 1995; Braunschweiger et al, 1996; Syljuasen
et al, 1997) provide an additional incentive for combining radio-
therapy with cytokine-transduced tumour vaccines. For example,
the expression of certain cytokines, such as interleukin-6 (IL-6)
and interferon alpha (IFN-a), have been shown to enhance
intrinsic radiosensitivity of tumour cells in vitro (McBride et al,
1995; Syljuasen et al, 1997). Data from Chiang et al (1997)
showed that IL-3-transfected fibrosarcomas regressed after 25 Gy
irradiation, whereas parental tumours regrew, suggesting that
manipulation of the tumour response to radiation therapy might be
possible by cytokine gene transfection. These results suggest that
the effects of cytokine expression locally within tumours may be
synergistic when used with another treatment modality and could
greatly increase the overall effectiveness of treatment, although
the mechanisms involved have yet to be determined.
We have previously shown that secretion of IL-2 within the
tumour microenvironment dramatically decreases the tumori-
genicity of EMT6, a mouse mammary tumour, and increases the
infiltration of host cells, including cytotoxic T-cells (McAdam et
al, 1994). In addition to the changes in the immune response, we
have also shown that these IL-2-transfected EMT6 tumours have
significantly decreased hypoxia compared to parental tumours
using EF5, a nitroimidazole compound that binds selectively to
hypoxic cells (Lee et al, 1998). Furthermore, using the fluorescent
dye Hoechst 33342 as an in vivo marker of perfused vessels,
combined with immunochemical staining of PECAM-1 (CD31) as
a marker of tumour vasculature, we found increased vasculariza-
tion in the IL-2-transfected tumours. In the current study, we
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investigated whether the expression of IL-2 by tumour cells alters
their radiosensitivity. Radiation sensitivity, as based on the clono-
genic cell survival assay, can be biased by the presence of non-
clonogenic host cells. To eliminate this potential bias, flow
cytometric analysis was used to determine the proportion of
tumour cells vs host cells in each tumour, thus correcting the
clonogenic data.
MATERIALS AND METHODS
Animals and reagents
BALB/cByJ mice were purchased from the Jackson Laboratory
(Bar Harbor, ME, USA), maintained in the AAALAC approved
vivarium of the University of Rochester Vivarium, and used at 
2–4 months of age. Guidelines for the humane treatment of
animals were followed as approved by the University Committee
on Animal Resources. G-418 sulphate was obtained from Gibco
Laboratories (Grand Island, NY, USA). Lipofectin was obtained
from Bethesda Research Laboratories (Gaithersburg, MD, USA).
Cells were cultured in EX-CELL 610 media from JRH Biologics
(Lenexa, KS, USA), with 100 U penicillin, 100 mg ml–1 strepto-
mycin, and 2% fetal bovine serum (FBS). Paramagnetic beads
(Dynabeads M-450) conjugated to sheep anti-rat-IgG were
obtained from Dynal Inc. (Great Neck, NY, USA).
Construction of the expression vector for IL-2
The murine IL-2 gene was obtained from the American 
Type Culture Collection and subsequently subcloned into the
SalI/BamHI cloning site of the vector pHb-Apr-1-neo (Gunning 
et al, 1987). The polymerase chain reaction was used to incorpo-
rate a SalI site at the 5¢ end and a BamHI site at the 3¢ end of the
gene. The final construct contained only the sequence within the
coding region (Yokota et al, 1985).
Cell lines and transfectants
EMT6.8 is a clone of EMT6, adapted to tissue culture from a
BALB/c (H-2d) mammary carcinoma, supplied by Dr Sara
Rockwell (Rockwell et al, 1972). EMT6.8 cells were transfected
using lipofectin, according to the manufacturer’s directions. At 
48 h after transfection, selection of transfectants was initiated with
400 mg ml–1 of G418; 10–14 days later, cells were cloned at
limiting dilution. Clones were expanded and tested for IL-2
production. The EMT6/IL-2 clone used in these studies produced
20–26 U ml–1 of IL-2 after 48 h of culture of 105 cells ml–1
(McAdam et al, 1994).
Tumour growth in vivo
Tumours were initiated with 2 ´ 105 cells for EMT6.8, or 106 cells
for EMT6/IL-2. The higher cell number for the EMT6/IL-2
tumours was used to compensate for their decreased tumori-
genicity and to provide tumours that grew at approximately the
same rate. Sixteen to 20 days later, the mice were sacrificed and
the tumours were removed.
EF5 synthesis and treatment
EF5, pentafluorinated derivative [2-(2-nitro-1H-imidazol-1-yl)-
N-(2,2,3,3,3-pentafluoropropyl)acetamide] of etanidazole was
synthesized by Dr R Vishnuvajjala of the National Cancer Institute
(Bethesda, MD, USA). Animals were injected intravenously with
0.2 ml of 10 mM EF5 in physiological saline, 3 h before the
tumour was removed for analysis.
EF5 binding/fluorescence assay
Tumours were minced with sharp scissors, dissociated in collage-
nase and filtered through a fine nylon mesh to obtain single 
cell suspensions for assays and for flow cytometric analysis.
Absence of cell clumps were verified during the haemocytometer
counts. Single-cell suspensions from tumours were fixed in 4%
paraformaldehyde (PFA) for 1 h at 4°C then washed three times 
in phosphate-buffered saline (PBS). Cells were resuspended in
blocking solution containing 5% normal mouse serum (NMS) in
PBS with 0.3% Tween-20 and 1.5% albumin overnight at 4°C.
Following blocking, cells were pelleted and the blocking solution
was aspirated away. A Cy3 (Amersham, Arlington Heights, IL,
USA) conjugated anti-EF5 (ELK3-51) antibody (Koch et al, 1995)
was added to the cell pellet at a concentration of 75 mg ml–1 in PBS
with 0.3% Tween-20 and 1.5% albumin. The cells were resus-
pended in the antibody and then placed on a rotator wheel for 6 h
at 4°C. Cells were then washed three times for 40 min each in PBS
with 0.3% Tween-20 on a rotator wheel and then resuspended in
1% PFA. Cells were examined on a Coulter Epics ELITE flow
cytometer as described previously (Koch et al, 1995).
Determination of the percentage of tumour-derived
host cells
Single-cell suspensions from tumours were stained with 10 mg ml–1
anti-CD45 monoclonal antibody (30-F11, PharMingen, San Diego,
CA, USA) for 30 min and followed by 20 mg ml–1 fluorescein
isothiocyanate (FITC)-conjugated mouse anti-rat IgG (Jackson
Immunoresearch Labs, West Grove, PA, USA) for 
30 min. Cells were washed, fixed overnight in 1% paraformalde-
hyde with 0.01% Tween-20 and then washed in PBS with 0.5%
FBS and 0.5% Tween-20. Following RNAase (90 units ml–1 in
PBS, Sigma, St Louis, MO, USA) treatment for 30 min, cells were
incubated with propidium iodide (10 mg ml–1) and stored in the
dark until analysis. Cells were examined on a Coulter Epics
ELITE flow cytometer.
Isolation of tumour-derived Thy-1 expressing cells
Thy-1-expressing cells were purified from tumours as previously
described (McAdam et al, 1994). Briefly, tumours were removed
and dissociated in collagenase (Type I, Sigma, St Louis, MO,
USA), and the tumour infiltrating lymphocytes (TILs) were puri-
fied using paramagnetic beads conjugated to anti-Thy-1.
Irradiation
Irradiation was performed on non-anaesthetized tumour-bearing
mice using a 137Cs source operating at a dose rate of 4.0 Gy min–1.
Each mouse was confined to a plastic jig with its tumour-bearing
leg extended through an opening in the side to allow the tumour to
be irradiated locally. Anoxia was induced in tumours by allowing
10 min after euthanasia before irradiation. Cells dissociated from
tumours were irradiated in suspension under aerobic conditions.IL-2 alteration of tumour radiosensitivity 939
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Plating efficiency assay
Clonogenic cell survival was determined immediately after irradi-
ation. Suitable numbers of dissociated cells were plated onto 
60-mm tissue culture dishes in EX-CELL 610 media supple-
mented with 5% FBS. Plates were incubated at 37°C for 14 days.
Media was removed and the cells were fixed with methanol,
stained with crystal violet and scored for colonies containing at
least 50 cells. The plating efficiency of individual cells from
tumours was calculated based on haemocytometer analysis of the
number of cells plated, then corrected based on the CD45-negative
tumour cell number. The survival curves were fitted by the multi-
target model (Chadwick and Leenhouts, 1973).
RESULTS
Determination of the relative percentage of host cells
vs tumour cells derived from tumours
We were interested in determining if the increased vascularization
we had previously observed in EMT6/IL-2 tumours altered the
sensitivity of the tumours to radiation. However, because the IL-2-
transfected tumours have more host cells than parental tumours
and these host cells are non-clonogenic (Howell and Koch, 1980),
we were concerned that the clonogenic cell survival assays used to
assess radiation sensitivity would be influenced by this difference.
However, due to the difficulty in visually distinguishing between
tumour cells and host cells when performing haemocytometer
counts, more reliable markers were needed to make this distinc-
tion. It is well-established that many tumours contain cells with
abnormal DNA content, whereas normal host cells are diploid
(Badalament et al, 1987). We analysed the DNA content of EMT6
cells grown in vitro by flow cytometry after staining with
propidium iodide for DNA content. Spleen cells were used as
controls to verify the DNA content of diploid host immune cells.
Although EMT6 cells were found to be tetraploid, the DNA
staining of EMT6 cells in the G1 phase of the cell cycle overlaps
that of host cells in G2 phase, which can result in a significant
source of error in estimating the content of host cells in tumours
(data not shown). As another marker to distinguish host cells from
tumour cells, we used CD45, also known as leucocyte common
antigen (LCA), which is expressed on host immune cells, but not
on tumour cells (Ledbetter and Herzenberg, 1979). Figure 1A and
B show the cells stained with propidium iodide and anti-CD45
antibody from in vivo EMT6 tumours and EMT6/IL-2 tumours
respectively. Diploid and CD45-positive host cells (represented in
box 1) can be distinguished from tetraploid and CD45-negative
tumour cells (represented in box 2). By using this approach, we
were able to quantify the relative percentages of host vs tumour
cells. In EMT6 tumours, approximately 68% of the cells are
tumour cells, whereas only 55% of the cells are tumour cells in
EMT6/IL-2 tumours. For all of the survival experiments, plating
efficiencies for each individual tumour were based on the
percentage of tetraploid, CD45-positive tumour cells present in the
cell suspension, as determined by this method.
In vivo radiation response of parental and IL-2
expressing EMT6 tumours
In order to determine if the production of IL-2 in situ within the
growing tumour altered the radiation sensitivity of the tumour
cells, size-matched EMT6 and EMT6/IL-2 tumours were irradi-
ated in either air-breathing or euthanized mice. Cell survival of the
irradiated tumours was determined by an in vitro plating efficiency
assay. The relative radiation resistances of the different tumours
are shown in Figure 2. The fraction of hypoxic cells was estimated
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Figure 1 Flow cytometric analysis of EMT6 (A) and EMT6/IL-2 (B) tumours to determine the relative percentage of host cells vs tumour cells. Cells derived
from tumours were stained for CD45 (leucocyte common antigen) followed by staining with propidium iodide for analysis of DNA content. Box 1 represents
diploid and CD45-positive host cells. Box 2 represents tetraploid and CD45-negative tumour cells. This is a representative histogram from one of the seven
experiments performed. A total of 25 tumours of each type were analysed. In EMT6 tumours the percentage (mean ± s.e.) of tumour cells was 68.1% ± 1.1,
whereas for EMT6/IL-2 tumours the percentage of tumour cells was 55.1% ± 1.6. The difference in these percentages were analysed by the Student’s t-test and
were significant at P < 0.0001940 J Lee et al
British Journal of Cancer (2000) 82(4), 937–944 © 2000 Cancer Research Campaign
from the ratio of the surviving fractions for air-breathing and
anoxic tumour at doses of 10 Gy and higher as shown in Figure 2
(Moulder and Rockwell, 1984). The dotted and dashed lines are
the best parallel lines which could be fitted for EMT6 and
EMT6/IL-2 tumours. The estimated hypoxic fractions with a 95%
confidence interval were 20 (14–27)% for IL-2 expressing
tumours and 43 (32–53)% for parental EMT6 tumours. Thus, it is
clear that the EMT6/IL-2 tumours are more radiosensitive than are
the parental EMT6 tumours.
Direct relationship between radiation survival and EF5
binding
We have previously demonstrated that EF5 binding can predict for
radiation resistance in rat (Evans et al, 1996) and mouse tumours
(Lee et al, 1996). To further evaluate the role of hypoxia in the
increased radiosensitivity observed in the EMT6/IL-2 tumours, we
compared binding of the 2-nitroimidazole drug, EF5, to the plating
efficiency of cells from individual EMT6 and EMT6/IL-2 tumours
after irradiation (12.5 or 15 Gy) in air-breathing mice. EF5 binding
to tumour cells was evaluated by flow cytometry, and the ratio of
the mean fluorescence intensity of the positively staining cells
from the tumours of mice receiving EF5 compared to intensity of
cells from mice that did not receive EF5 is plotted. A direct rela-
tionship between these two measurements was observed (Figure
3), further supporting the importance of tumour hypoxia in the
radiosensitivity differences observed between the two tumour
types.
Influence of cytotoxic T-cells on plating efficiency
We have previously demonstrated that IL-2 secreting EMT6
tumours contain greatly increased numbers of TILs, which are
lytic for EMT6 cells, and in some cases comprise more than 10%
of the total cells obtained from the tumours (Lee et al, 1998). Thus,
another consideration was whether cytotoxic T-cells in the cell
suspensions from the EMT6/IL-2 tumours might be capable of
lysing tumour cells during the plating efficiency determinations.
We purified Thy-1-expressing cells from tumours using paramag-
netic beads indirectly conjugated to anti-Thy-1, and compared the
plating efficiency of whole tumour, Thy-1-positive cells, Thy-1-
negative cells, and a recombined mixture of Thy-1-positive and
-negative cells (Figure 4). As expected, the plating efficiency of
EMT6 tumours was not affected by depleting Thy-1-positive cells
(Figure 4A), because EMT6 tumours have only a small percentage
of TILs (<3%), and these TILs exhibit minimal lysis of EMT6
cells (Lee et al, 1998). Recombining Thy-1-positive cells with
Thy-1-negative cells (tumour cells and other host cells) in equal
proportions also did not influence the plating efficiency. Similar
results were obtained from IL-2-expressing EMT6 tumours
(Figure 4B), even though these tumours have an increased number
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Figure 2 Surviving fraction of tumours after irradiation in vivo. n, EMT6
tumours irradiated in euthanized animals; n n, EMT6/IL-2 tumours irradiated in
euthanized animals; l, EMT6 tumours irradiated in air-breathing animals; l l,
EMT6/IL-2 tumours irradiated in air-breathing animals. Each data point
represents the mean ± s.e. of 3–6 tumours assessed in three independent
experiments. Lines are best fits to the individual data sets and assume multi-
target kinetics.
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Figure 3 Relationship between plating efficiency and the ratio of mean
fluorescence (plus or minus EF5) of cells from EMT6 (n) and EMT6/IL-2
tumours (l l). Tumour-bearing mice were injected with EF5 and tumour-
bearing legs were exposed to 12.5 Gy (A) or 15 Gy (B). Tumours were
removed and dissociated. One portion of cells was stained for EF5 binding,
as described in Materials and Methods, whereas the remaining portion of
cells was plated for survival analysis. Each data point represents an
individual tumour.IL-2 alteration of tumour radiosensitivity 941
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of TILs, which lysed EMT6 cells very effectively (Lee et al,
1998). This lack of any apparent cytotoxicity of the TILs during
the plating efficiency assay is probably due to the much lower cell
densities in these assays compared to the standard cytotoxicity
assays. These cell densities are probably not conducive to the cell-
to-cell contact that is required for T-cell-mediated lysis. Therefore,
in these assays we can exclude the possibility that cytotoxic T-cells
present in the IL-2-expressing tumours influence the clonogenic
assay.
Intrinsic radiation sensitivity of EMT6/IL-2 cells
An additional consideration was the possibility of intrinsic differ-
ences in the radiosensitivity of EMT6/IL-2 cells and EMT6 cells.
Such differences could be due to the presence of the IL-2 gene or
the fact that a clone of the original cells was selected during the
transfection procedure. To assess this possibility, EMT6 and
EMT6/IL-2 cells growing in vitro were irradiated at various doses
and survival determined. Indeed, the EMT6/IL-2 line was found to
have an increased in vitro sensitivity to radiation (Figure 5).
However, the survival of EMT6/Neo, transfected with the
neomycin gene only, was similar to EMT6 cells, suggesting that
insertion of the control vector does not affect radiosensitivity.
Studies by others have suggested that altered cell proliferation and
cell cycle distribution are likely to impact intrinsic radiosensitivity
(Chang and Keng, 1987; Hill, 1986; Kwok and Sutherland, 1992).
However, we found no differences in either growth rate or the cell
cycle distribution between EMT6 and EMT6/IL-2 cells (Table 1).
To determine whether the difference in intrinsic radiosensitivity
between EMT6 and EMT6/IL-2 cells also existed in tumours
growing in vivo, cells were dissociated from tumours and then
irradiated in suspension. Figure 6 demonstrates that cells from
EMT6/IL-2 tumours are more sensitive to irradiation than those
from EMT6 tumours, suggesting differences in the intrinsic
radiosensitivities between the two tumour types. Each of the
survival curves shown in Figure 6 was fitted using the multitarget
model (Chadwick and Leenhouts, 1973), and the curves used to
evaluate the oxygen enhancement ratio (OER). The OER for
EMT6 tumours was 2.42 and 2.5 for EMT6/IL-2 tumours, thus the
lack of difference between the two tumours also indicates some
intrinsic difference in the cell lines.
DISCUSSION
In this study, we have shown that the decreased hypoxic cell frac-
tion observed in EMT6 mammary tumours transfected with the
gene for IL-2 (Lee et al, 1998) results in increased radiation sensi-
tivity of the tumours growing in vivo. The importance of hypoxic
cells in limiting the radiation response in both animal and human
tumours is well recognized (Moulder and Rockwell, 1984;
Gatenby et al, 1988; Hockel et al, 1993). These results are thus in
accordance with the model that tumours with decreased hypoxia
(in this case due to expression of IL-2) have greater radiosensi-
tivity. Results of several control experiments verified that the
differing radiosensitivity observed was due to the microenviron-
mental differences present within the two types of tumours and not
due to the presence of host cells confounding the in vitro plating
efficiency assay. Host cells were enumerated based on their
diploid DNA content and their expression of the CD45 cell surface
marker thus allowing correction of the plating efficiency data.
Although not necessary for all studies, it is important to make such
corrections when comparing tumours having large differences in
the host cell populations. This approach has the advantage of being
applicable to a wide range of both experimental and human
tumours. In addition, although there was a marked difference in
the number and cytolytic activity of the lymphocytes present
within the two types of tumours, the presence of such cytolytic
host cells had no effect in the plating efficiency assay. This
suggests that in most tumour systems, the presence of lytic host
cells will have only minimal effects on the outcome of plating effi-
ciency assays. Interestingly, the EMT6/IL-2 expressing line used
in these experiments appeared to be inherently more radiosensitive
than the parental cell line. Since there were no differences in the
cell cycle and the proliferation rate, we think that the most likely
explanation for the differing intrinsic radiation sensitivity between
the two cell lines is clonal variation.
The response to radiation of tumours growing in vivo is influenced
by numerous extrinsic factors within the tumour microenvironment,
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Figure 4 The effect of TILs on the plating efficiency of cells derived from
EMT6 (A) and EMT6/IL-2 (B) tumours. Thy-1-expressing cells were purified
from tumours using paramagnetic beads conjugated to anti-Thy-1. The
plating efficiencies of whole tumour, Thy-1-positive cells, Thy-1-negative
cells, and the recombined mixture of equal numbers of Thy-1-positive and
-negative cells were compared. These results are from one representative
experiment of three performed. Shown are the means ± s.d. of three
individual tumours of each type. As analszed by the Student’s t-test there is
no statistically significant difference between the values for the cells from the
whole tumour and the Thy-1-negative cells for either tumour type.942 J Lee et al
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Figure 5 The in vitro cell survival of EMT6 (n), EMT6/Neo (s), and EMT6/IL-2 (l) cells following various doses of irradiation. The data are representative of
three independent experiments. Each symbol is the mean ± s.e. of three cultures per dose. Lines are best fits to the individual data sets and assume multi-
target kinetics
Table 1 Cell cycle analysis of EMT6 and EMT6/IL-2 cells grown in vitro
Cells in G1 (%) Cells in S (%) Cells in G2 (%)
EMT6 42.4 36.4 21.2
EMT6/IL-2 44.9 33.7 21.4
Cells were stained with propidium iodide, and DNA histograms were
analysed using the multicycle program (Phoenix Flow System, San Diego,
CA) on a Coulter EPICS Elite flow cytometer.
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Figure 6 Surviving fraction of anoxic tumours and tumours cells irradiated in suspension. n, EMT6 tumours irradiated in euthanized animals (anoxia); n n,
EMT6/IL-2 tumours irradiated in euthanized animals; l, EMT6 tumour-derived cells irradiated in suspension (aerobic); l l, EMT6/IL-2 tumour-derived cells
irradiated in suspension. The aerated curve was generated by irradiating cells dissociated from tumours with graded radiation doses, and the hypoxia curve was
generated from tumours irradiated in euthanized animals. Each data point for the anoxic curves represents the mean ± s.e. of 3–6 tumours in four independent
experiments. Each data point for the aerobic curves represents the mean ± s.e. of three cultures per dose with pooled tissue from three tumours. Lines are best
fits to the individual data sets and assume multi-target kineticsin addition to the intrinsic radiosensitivity of the cell line. Tumour
oxygenation is an extremely important modifier of the radiation
response in the complex in vivo situation. We have previously
shown that alteration of oxygenation by drug treatment or by
carbogen breathing in murine KHT tumours results in an altered
radiation response (Lee et al, 1996). Furthermore, in that study
there was a direct relationship between the radiation response and
the level of hypoxia, as measured by binding of the nitroimidazole,
EF5. In the current study, where the modification of oxygenation
was induced by IL-2 gene transfer, we have observed the same
relationship between EF5 binding and radiosensitivity. Although
we cannot exclude the possibility that the slightly altered intrinsic
radiosensitivity of EMT6/IL-2 cells might also contribute to the
radiosensitivity of EMT6/IL-2 tumours observed in vivo, our
results strongly suggest that the increased radiosensitivity of
EMT6/IL-2 tumours is mainly due to the decreased hypoxia in
these tumours.
The increased vascularization and decreased hypoxia resulting
in enhanced radiosensitivity that we have observed in the
EMT6/IL-2 tumours provide support for combining cytokine
therapy and radiotherapy to enhance tumour control. The possi-
bility of combining these two therapy modalities has been the
subject of relatively few studies. In one study it was found that
combined treatment of IL-2 and TILs with local irradiation for
liver metastasis in mice was more effective than single modality
treatments (Cameron et al, 1990). The explanation given for this
result was that local irradiation may be needed to decrease tumour
bulk and to slow the tumour growth such that the rate of tumour
cell lysis by TILs exceeds that of tumour growth. However, it is
also possible that additional effects could be occurring. More
recent reports from McBride and colleagues (McBride et al, 1995;
Syljuasen et al, 1997) explored the possibility that cytokine gene
transfer could be used to modify tumour radioresistance. This
same group has also shown that an IL-3-transfected fibrosarcoma
regressed after 25 Gy irradiation, whereas the parental tumour
regrew, concluding that IL-3-transfected tumours are more sensi-
tive than parental tumours to irradiation in vivo (Chiang et al,
1997). Interestingly, greatly increased host cell infiltration was
observed in the IL-3-expressing tumours, suggesting that the
regression was probably immune-mediated. In another study we
have shown that IL-3 stimulates a population of antigen presenting
cells (APCs) that leads to an enhanced T-cell-mediated immunity
(Pulaski et al, 1996). As illustrated by the current study, IL-2
would appear to be an especially effective cytokine for combina-
tion therapy with radiation. Its ability to increase vascularization
and decrease hypoxia within the tumours as previously shown
(Lee et al, 1998), makes a much larger proportion of the tumour
cells susceptible to radiation therapy. In addition, since the T-cells
appear to infiltrate only short distances from the vessels into the
tumours (Lee et al, 1998), the increased vascularization allows the
T-cells stimulated by the IL-2 to access much more of the tumour.
An additional rationale for the use of IL-2 is evidence
suggesting that IL-2 provides a radioprotective effect for some
immune cells (Hietanen et al, 1995; Seki et al, 1995; Mor and
Cohen, 1996). There has long been the concern that local irradia-
tion might destroy the very immune cells that are likely to be the
most tumour reactive, i.e. those present within the tumours and
draining lymph nodes. Early studies (James et al, 1983; Gerber et
al, 1989) demonstrated that IL-2 added to cultures of human T-
cells made them more radioresistant. Similar effects have also
been observed with natural killer cells (Hietanen et al, 1995).
Similarly, work on peripheral lymphocyte populations isolated
from humans (Seki et al, 1995) and rats (Mor and Cohen, 1996)
has shown that IL-2 rescues T-cells from radiation-induced apop-
tosis, and that this was associated with induction of Bcl-2, a
protein that protects cells from cell death. If indeed additional IL-2
could provide a protective effect by preventing or lessening radia-
tion-induced apoptosis of host lymphoid cells, this would be an
additional bonus for combining these modes of therapy.
Although the increase in radiosensitivity between the EMT6 and
the EMT6/IL-2 tumours was not dramatic, even relatively small
differences could have significant effects in a typical multifraction
radiation treatment. Reoxygenation as well as initial hypoxic frac-
tion, may also have a significant effect on tumour cure. However,
these effects have not yet been studied in this system. The multiple
effects observed for IL-2 on not only the immune system, but also
the physical microenvironment, provides incentive to further
explore the feasibility of combination therapies. A better under-
standing of the mechanisms involved in these cytokine-induced
alterations will allow more effective use of these techniques to
control malignancy.
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